Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EBMT 2022 | The benefits of GvHD risk stratification

Ernst Holler • 21 Mar 2022
EBMT 2022
General

Ernst Holler, MD, University Hospital Regensburg, Regensburg, Germany comments on the benefits of risk stratification for graft-versus-host disease (GvHD). Currently, risk stratification is based either on clinical risk or on the identification of specific biomarkers, but in the future, these may merge into a model combining both clinical factors and biomarkers, resulting in a more accurate approach to predict both chronic and acute GvHD. GvHD is typically managed with glucocorticoids, which are known to have important side effects. Prof. Holler explains that risk stratification models may help determine the appropriate dose of glucocorticoids for each individual patient, thereby avoiding unnecessary side effects. This interview took place at the 48th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) 2022, which was held virtually.

More from Ernst Holler

The pathophysiology of chronic GvHD: current understanding and unanswered questions
8:37
The pathophysiology of chronic GvHD: current understanding and unanswered questions
Ernst Holler • 19 Apr 2024
The relationship between the gut microbiome and GvHD
16:41
The relationship between the gut microbiome and GvHD
Ernst Holler • 19 Apr 2024
Pathophysiology of GvHD
2:39
Pathophysiology of GvHD
Ernst Holler • 21 Mar 2022
Modulation of the microbiota for the treatment of GvHD
4:34
Modulation of the microbiota for the treatment of GvHD
Ernst Holler • 21 Mar 2022

Related Videos

Key principles for implementing AI tools into clinical practice
3:19
Key principles for implementing AI tools into clinical practice
Adrián Mosquera Orgueira • 24 Sep 2026
Current role of AI in hematology/oncology: separating the hype from reality
2:54
Current role of AI in hematology/oncology: separating the hype from reality
Adrián Mosquera Orgueira • 24 Sep 2026
Addressing the risk of over-reliance on AI for clinical decision-making
2:25
Addressing the risk of over-reliance on AI for clinical decision-making
Adrián Mosquera Orgueira • 24 Sep 2026
Telomere dynamics in normal and pathological aging
12:41
Telomere dynamics in normal and pathological aging
Coleman Lindsley • 18 Sep 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals